The Discounted Cash Flow (DCF) valuation of Coherus BioSciences Inc (CHRS) is (25.87) USD. With the latest stock price at 1.73 USD, the upside of Coherus BioSciences Inc based on DCF is -1595.1%.
Based on the latest price of 1.73 USD and our DCF valuation, Coherus BioSciences Inc (CHRS) is a sell. selling CHRS stocks now will result in a potential gain of 1595.1%.
Note: valuation result may not be accurate due to the company's negative cashflows.
| Range | Selected | |
| WACC / Discount Rate | 6.1% - 8.7% | 7.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (77.68) - (16.06) | (25.87) |
| Upside | -4590.3% - -1028.3% | -1595.1% |